Pfizer Paid Out $14.6 Billion in Dividends — Can It Keep the Pace?

Over the past 18 months, Pfizer paid out a staggering $14.6 billion in dividends, underscoring its commitment to shareholder returns even as the post-pandemic revenue boom fades. Yet the pharmaceutical giant is bracing for a significant challenge: patents on several blockbuster drugs are set to expire in the coming years, potentially opening the door to generic competition. This patent cliff threatens to erode billions of dollars in annual revenue and could jeopardize the sustainability of the dividend. Pfizer is actively pursuing acquisitions and investing in its drug pipeline to offset the anticipated losses. Analysts are divided, with some believing the company can navigate the transition and others warning of a potential dividend cut. For income-focused investors, the situation warrants close attention to upcoming quarterly earnings reports.